A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

<p>Abstract</p> <p>Background</p> <p>To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel (D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC).</p> <p>Methods</p> <...

Full description

Bibliographic Details
Main Authors:	Pavlakou Georgia, Kentepozidis Nikolaos, Syrigos Kostas, Varthalitis Ioannis, Agelidou Athina, Agelaki Sophia, Pallis Athanasios G, Kotsakis Athanasios, Kontopodis Emmanouel, Georgoulias Vassilis
Format:	Article
Language:	English
Published:	BMC 2010-11-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/10/633

Similar Items

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
by: Abdel Kader Y, et al.
Published: (2013-06-01)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01)

Tumor lysis syndrome associated with docetaxel and carboplatin in a case with recurrent endometrial cancer
by: Tomomichi Ito, et al.
Published: (2018-05-01)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
by: Boutsikou E, et al.
Published: (2013-03-01)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
by: Miguel Martin, et al.
Published: (2021-03-01)

Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma
by: Lv X, et al.
Published: (2016-08-01)

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel
by: Armstrong Stephen R, et al.
Published: (2012-11-01)

Clinical outcome of docetaxel in advanced or metastatic endometrial cancer
by: Rasha Hamdy Hamed, et al.
Published: (2012-07-01)

A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
by: Chengcheng Gong, et al.
Published: (2017-07-01)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
by: Maria Elisabeth Lendorf, et al.
Published: (2021-02-01)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
by: Jie Xu, et al.
Published: (2018-10-01)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
by: Ietsen de Groot, et al.
Published: (2021-11-01)

Effect of docetaxel + oxaliplatin + S-1 and docetaxel + cisplatin + fluorouracil on treatment of advanced gastric cancer
by: Wei Li, et al.
Published: (2016-09-01)

Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
by: Hugo Ford, et al.
Published: (2015-07-01)

Docetaxel-related interstitial pneumonitis
by: Wang CJ, et al.
Published: (2015-12-01)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
by: Harkirat Singh Talwar
Published: (2021-01-01)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
by: Manuel Caitano Maia, et al.
Published: (2017-03-01)

Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma
by: Osama Diab, et al.
Published: (2019-01-01)

Docetaxel-induced hand and foot syndrome in a patient with metastatic breast carcinoma
by: Ravichandran Gurumurthi, et al.
Published: (2013-01-01)

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
by: Judith Passildas‐Jahanmohan, et al.
Published: (2021-04-01)

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
by: Touroutoglou Nikolaos, et al.
Published: (2007-05-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

Current problems in the first-line treatment of metastatic breast cancer: focus on the role of docetaxel
by: Filippo Montemurro
Published: (2010-09-01)

Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report
by: Ryo Fujiwara, et al.
Published: (2015-08-01)

Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma
by: Peng PJ, et al.
Published: (2015-12-01)

Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2016-09-01)

PSA flare in metastatic castration-resistant prostate cancer patients treated with abiraterone or docetaxel
by: Hui-Ying Liu, et al.
Published: (2016-06-01)

Docetaxel interacts with aryl hydrocarbon receptor
by: 程啟嘉
Published: (2018)

Undifferentiated prostate cancer treated with docetaxel
by: Masaki Kobayashi, et al.
Published: (2020-07-01)

Periungual lesions secondary to chemotherapy with docetaxel
by: Dawid Sigorski, et al.
Published: (2020-02-01)

Adverse reactions to docetaxel: an active survey
by: Leandro Cabral Pereira, et al.
Published: (2015-09-01)

Preparation and Characterization of Self-Emulsified Docetaxel
by: Gyeong Hae Kim, et al.
Published: (2011-01-01)

Severe Photo Toxicity Recalled by Docetaxel
by: Emma K. Johansson, et al.
Published: (2018-11-01)

Docetaxel Retinopathy: A Case Report
by: Sylvia Nghiem-Buffet, et al.
Published: (2017-01-01)

Review of docetaxel in the treatment of gastric cancer
by: Eric D Tetzlaff, et al.
Published: (2008-09-01)

The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance
by: Lorenzo Bascetta, et al.
Published: (2017-07-01)

Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial
by: Safa Najafi, et al.
Published: (2017-03-01)

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
by: Joseph M. Unger, et al.
Published: (2018-06-01)

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
by: Maria A. Papadaki, et al.
Published: (2021-01-01)